Shanghai Junshi Biosciences' (SHA:688180, HKG:1877) unit, Shanghai Juntope Biopharmaceutical, will conduct clinical trials on the JT118 injection after obtaining the approval of China's National Medical Products Administration, according to a Thursday filing on the Shanghai bourse.
The Chinese biopharmaceutical company will test the vaccine's safety and efficiency as a prevention of the monkeypox virus infection.
The company's shares jumped less than 5% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.